887129-63-7

Upstream product

• 887129-62-6 4-(4-fluoro-phenyl)-isothiazolidine-1,1-dioxide 
• 190367-50-1 4-fluoro-5-methanesulfonyl-2-methyl-benzoic acid methyl ester 
• 7440-44-0 pyrographite 

Downstream Products

• 887129-47-7 N-{4-[4-(4-fluorophenyl)-1,1-dioxoisothiazolidin-2-yl]-5-methanesulfonyl-2-methylbenzoyl}guanidine 
• 887129-47-7 N-{4-[4-(4-fluorophenyl)-1,1-dioxoisothiazolidin-2-yl]-5-methanesulfonyl-2-methylbenzoyl}-guanidine 

Relevant academic research and scientific papers

SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT OR DIAGNOSTIC AND MEDICAMENT COMPRISING THE SAME

The present invention relates to substituted benzoylguanidines of the formula I: in which R1 to R8 and X and Y are as described in the specification, and their pharmaceutically acceptable salts are substituted acylguanidines as inhibitors of the cell

SUBSTITUTED BENZOYLGUANIDINES METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT OR DIAGNOSTIC AND MEDICAMENT COMPRISING THE SAME

The invention relates to substituted benzoylguanidines of formula (I), where R1 to R8, X and Y have the meanings given in the claims and the pharmaceutically-acceptable salts thereof which are substituted acylguanidines and inhibit cellular Sodium/Proton antiporter (Na+/H+-Exchanger, NHE). Compounds of formula (I) and the pharmaceutically-acceptable salts thereof are suitable for the prevention and treatment of disease caused by activation of or by an activated NHE as a result of the NHE-inhibitory properties thereof and also of secondary diseases caused by damage brought about by the NHE.